CompletedNCT04398225
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
This study evaluated the safety of Centanafadine for people with ADHD.
Medication studyAges 4–12United States
Understand this study
What did researchers investigate?
This study evaluated the safety of Centanafadine for people with ADHD.
Who was this study for?
Listed age limits: 4 years to 12 years.
- Listed locations
- HollywoodSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 11, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 4 Years to 12 Years
- Official registry ID
- NCT04398225
- Official title
Show the full official title
A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-deficit/Hyperactivity Disorder
Get this study by email
Recruitment & locations
CompletedHollywood
Questions about this study
What did researchers investigate?
This study evaluated the safety of Centanafadine for people with ADHD.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Centanafadine.
Who was this study for?
Listed age limits: 4 years to 12 years.
